News Europa - pubblicata il 23 Aprile 2024
Source: European Commission Spokesperson's Service
The European Commission invites comments on commitments offered by Vifor to address competition concerns over the alleged disparagement of its closest – and potentially only – competing treatment in Europe for intravenous iron treatment, Pharmacosmos’ Monofer.
Following the opening of a formal investigation in June 2022, the Commission preliminarily found that Vifor is dominant in several national markets for the provision of intravenous iron medicines, namely in Austria, Finland, Germany, Ireland, Portugal, Romania, Spain, Sweden and The Netherlands. The Commission is concerned that Vifor may have restricted competition in the market for intravenous iron treatment by illegally disparaging Monofer, an iron deficiency treatment by its closest competitor in Europe, Pharmacosmos.
To address the Commission’s competition concerns, Vifor has offered a number of commitments, which would be monitored by a monitoring trustee appointed by Vifor, who would report to the Commission for a period of 10 years.
The Commission invites all interested parties to submit their views on Vifor’s proposed commitments within one month from the publication of a summary of the proposed commitments in the EU’s Official Journal.
A press release is available online.